We advance superior mAb therapeutics to improve the lives of cancer patients
Symphogen is a privately-owned biotech company focused on oncology and immuno-oncology. We have a highly efficient antibody discovery and research platform supported by comprehensive early development capabilities.
Our antibody platform delivers antibodies with unique functionalities providing best or first in class potential as combination or mono therapy. Our approach and capabilities are well suited for combination therapies at the core of future cancer treatment.
Symphogen’s integrated R&D approach delivers productive end-to-end drug development that has generated five INDs in the last three years. Our platform is validated by partners in the immuno-oncology and infectious disease fields and we continue to seek additional partners to advance our novel antibody strategies to patients.